Physician profile

Catalina Dinu

Obstetrics & Gynecology · East Stroudsburg, PA

NPI 1730184110

$278.56

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$41.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Molnlycke Health Care US, LLC $114.92 2021
Abbvie INC. $41.98 2019-2021
Sumitomo Pharma America, INC. $25.75 2024 Myfembree
Dysis Medical, INC. $24.45 2022
Hologic Sales and Service, LLC $16.24 2019
Mycovia Pharmaceuticals, INC. $16.08 2023 Vivjoa
Pfizer INC. $13.49 2022
Agile Therapeutics, INC. $13.13 2021
Millicent US INC $12.52 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Catalina Dinu

$278.56

in general payments reported 2019-2025

Years
2019-2024
Top company
Molnlycke Health Care US, LLC

https://glasscript.com/doctor/526381/catalina-dinu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.